Key Insights

Highlights

Success Rate

92% trial completion (above average)

Published Results

13 trials with published results (15%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.7%

4 terminated out of 86 trials

Success Rate

92.0%

+5.4% vs benchmark

Late-Stage Pipeline

12%

10 trials in Phase 3/4

Results Transparency

28%

13 of 46 completed with results

Key Signals

13 with results92% success

Data Visualizations

Phase Distribution

55Total
Not Applicable (26)
P 1 (3)
P 2 (16)
P 3 (4)
P 4 (6)

Trial Status

Completed46
Unknown15
Recruiting12
Not Yet Recruiting6
Terminated4
Active Not Recruiting2

Trial Success Rate

92.0%

Benchmark: 86.6%

Based on 46 completed trials

Clinical Trials (86)

Showing 20 of 20 trials
NCT07822880Phase 4Not Yet RecruitingPrimary

A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India

NCT01005654Recruiting

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

NCT00467506Phase 2CompletedPrimary

Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

NCT07812779Not Yet Recruiting

Thyroid Health Outcomes Registry for Surgery

NCT05241834Phase 1Completed

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT04139096CompletedPrimary

Genetic Susceptibility to Radiation Induced Thyroid Cancer

NCT07628543Not Yet Recruiting

Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery

NCT07575243Completed

Thyroidectomy-specific Enhanced Recovery After Surgery (ERAS) Protocol

NCT01398085Phase 2Active Not Recruiting

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT06220656Not ApplicableRecruiting

TRAIL Study: Feasibility and Pilot

NCT03573960Phase 4CompletedPrimary

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

NCT07447089Not ApplicableRecruitingPrimary

EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study

NCT07434206Phase 2Active Not RecruitingPrimary

Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors

NCT07419932Recruiting

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

NCT06853925Not ApplicableRecruitingPrimary

Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

NCT03160274Recruiting

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

NCT05022667Not ApplicableCompletedPrimary

Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy

NCT05579782Not ApplicableCompleted

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

NCT07033572Not ApplicableRecruitingPrimary

Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma

Scroll to load more

Research Network

Activity Timeline